Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Merck & Co., Inc.    MRK

Delayed Quote. Delayed  - 05/26 10:00:19 pm
56.39 USD   -0.32%
05/26 MERCK : Corporate Social Responsibility Related News Releases and St..
05/24 MERCK : Announces Third-Quarter 2016 Dividend
05/24 MERCK : to Present at the UBS Global Healthcare Conference
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Merck & Co., Inc. : Merck To Pay $321.6 Million Fine For Illegal Marketing Of Vioxx

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/19/2012 | 07:50pm CEST

A U.S. district court judge in Boston ordered Merck & Co. (MRK) to pay a $321.6 million criminal fine for its violation of a federal drug law in connection with its marketing of the former painkiller Vioxx.

In December, Merck pleaded guilty to violating the Federal Food, Drug, and Cosmetic Act for introducing a misbranded drug into interstate commerce. The company said it previously recorded a $950 million charge in October 2010 in anticipation of the settlement, which resolves a seven-year investigation.

Merck withdrew Vioxx from the market in 2004 after it was linked to a higher risk of heart attacks and strokes.

"The government recognized Merck's full cooperation with its investigation and by putting this long-standing investigation to rest, we can more fully focus on discovering, developing and providing innovative medicines and vaccines that save and improve lives around the world," Merck said in a statement.

In November, Merck had agreed to pay $950 million and plead guilty to a misdemeanor charge of marketing a misbranded drug, to resolve government allegations that the company illegally promoted Vioxx and deceived the government about the drug's safety. The government alleged that Merck promoted Vioxx for treatment of rheumatoid arthritis before that use was approved by regulators. A portion of the $950 million settlement also was to resolve parallel civil allegations that Merck made false and misleading statements about Vioxx's safety, causing government health programs to pay for the drug's use. Merck denied the civil allegations.

Shares were off 14 cents to $38.26 in recent trading. The stock is up 1.5% since the start of the year.

-By Nathalie Tadena, Dow Jones Newswires; 212-416-3287; nathalie.tadena@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
React to this article
Latest news on MERCK & CO., INC.
05/26 MERCK : Corporate Social Responsibility Related News Releases and Story Ideas fo..
05/24 MERCK : Announces Third-Quarter 2016 Dividend
05/24 MERCK : to Present at the UBS Global Healthcare Conference
05/24 MSD ANIMAL HEALTH : Receives Marketing Approval from European Medicines Agency f..
05/24 MERCK : Announces FDA Accepts Samsung Bioepis’ Biologics License Applicati..
05/23 MERCK : Foundation Announces the Alliance to Advance Patient-Centered Cancer Car..
05/23DJGermany's Bayer Offers $62 Billion in Cash for Monsanto
05/19DJGermany's Bayer Breaks With Caution in Monsanto Bid
05/19DJMERCK : New Hope for Melanoma Patients -- Update
05/18 MERCK : New KEYTRUDA® (pembrolizumab) Data from KEYNOTE-006 and KEYNOTE-001 in A..
Advertisement
News chart
Full-screen chart
Income Statement Evolution
More Financials